Clinical trial HATCY study
A Phase III, multicenter, randomized controlled study to compare safety and efficacy of a haploidentical HSCT and adjunctive treatment with ATIR101, a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells, versus a haploidentical HSCT with post-transplant cyclophosphamide in patients with a hematologic malignancy
Cancers | |
---|---|
Organ | Multiple |
Trial status | Trial closed |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | Kiadis Pharma |
EudraCT Identifier | 2016-004672-21 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02999854 |
Inclusion criteria | no suitable HLA-matched sibling or unrelated donor / no prior allogeneic stem cell transplantation/ AML, ALL or MDS |
Last update |